Novo Nordisk shareholders are suing the drugmaker over its experimental weight problems remedy CagriSema, alleging the corporate misled traders a few key scientific trial earlier than releasing disappointing outcomes that wiped billions of {dollars} off its market worth.
A federal decide on Tuesday allowed components of that lawsuit to maneuver ahead, discovering that traders had plausibly alleged that some statements about CagriSema’s tolerability and the design of the late-stage trial could have been deceptive.
The ruling doesn’t decide that Novo dedicated securities fraud. As an alternative, it means the case can proceed into the subsequent stage, the place traders can search proof supporting their claims.
A Novo Nordisk spokesperson mentioned the corporate “believes that the allegations towards it are meritless,” and intends to vigorously defend towards them.
It comes as Novo works to spice up investor confidence in its weight problems enterprise amid mounting competitors from Eli Lilly and because it bets closely on its subsequent era of weight-loss remedies.
Here is what occurred, what the lawsuit alleges, and why CagriSema has grow to be so vital to Novo’s future.
What traders allege
The case facilities on CagriSema, an experimental weekly injection that mixes semaglutide — the energetic ingredient in Wegovy and Ozempic — with cagrilintide, which mimics the hormone amylin.
When Novo launched CagriSema topline ends in December 2024, traders had broadly anticipated the remedy to provide common weight lack of roughly 25%. As an alternative, the corporate reported common weight lack of about 20.4% in apply, sending the inventory sharply decrease.
Shareholders argue they weren’t adequately knowledgeable earlier than these outcomes that the REDEFINE-1 research used a versatile dosing method that allowed members to regulate their doses through the research, relatively than requiring everybody to escalate to the utmost degree. Solely 57% of members finally reached the very best dose.
Traders additionally allege that Novo appeared that the Part 3 REDEFINE-1 trial would observe a dosing method just like earlier trials, together with a hard and fast upkeep dose of two.4 milligrams of semaglutide mixed with 2.4 milligrams of cagrilintide.
Traders argue that the disclosure modified how the market understood the trial outcomes, notably round how properly sufferers tolerated the remedy on the highest dose.
The excellence issues as a result of the courtroom famous that the extent to which sufferers can stay on a remedy on the supposed dose, or drug tolerability, is a key challenge for weight problems medicines.
“Medical trials are sophisticated and nuanced, and investor calls usually are not scientific conferences,” Choose Robert Kirsch wrote in a 56-page opinion. However he added that pharmaceutical corporations can not mischaracterize or omit vital elements of scientific trials in a deceptive manner.
Novo has denied wrongdoing.
Following the December announcement, Novo’s American depositary receipts fell $18.15 per share, or 17.83%, in a single day, with greater than 53 million shares traded, based on the ruling. Copenhagen-listed shares dropped 20.7%.
What the decide determined
The decide rejected many of the shareholders’ allegations, discovering that traders had not sufficiently proven that lots of the firm’s statements about CagriSema’s weight-loss potential, future trials or different points had been actionable below securities legislation.
However he allowed claims associated to CagriSema’s tolerability and REDEFINE-1’s scientific protocols to proceed.
The courtroom discovered that traders had plausibly alleged that sure statements in regards to the trial design might have been deceptive. These included statements describing REDEFINE-1 as utilizing a fixed-dose mixture and feedback from Martin Holst Lange, Novo’s former govt vp of improvement and present chief scientific officer, in regards to the drug’s tolerability profile and dosing method.
The decide additionally discovered that traders had sufficiently alleged the required degree of intent for claims involving Lange.
The courtroom pointed to allegations that Lange had been offered to traders as a key govt chargeable for answering questions on Novo’s scientific trial design and outcomes.
The ruling doesn’t determine whether or not these allegations are true. It solely determines that the claims meet the authorized customary to maneuver ahead.
Why CagriSema issues a lot
The lawsuit comes at a tough time for Novo.
The corporate constructed the fashionable weight problems drug market with Wegovy and Ozempic, however it has confronted rising strain from Eli Lilly’s rival medicines, which have quickly gained market share.
That competitors has made Novo’s pipeline more and more vital to traders. The corporate is relying on merchandise together with higher-dose Wegovy, oral variations of its medicines and CagriSema to assist strengthen its place out there.
Novo has seen CagriSema as an vital subsequent step in its weight problems pipeline, beforehand pointing traders towards the drug’s potential to ship larger weight reduction with minimal uncomfortable side effects.
Novo has pushed again towards the concept that CagriSema’s preliminary trial outcomes represented a failure. CEO Mike Doustdar instructed CNBC earlier this yr that the market had “penalized” the info harshly and mentioned additional research would offer a fuller image of the drug’s potential.
This lawsuit is separate from Novo’s case towards Eli Lilly
The shareholder lawsuit is unrelated to Novo’s latest authorized battle with Eli Lilly.
Final week, Novo sued Lilly, alleging that Lilly’s commercials unfairly evaluate its medicine with older, decrease doses of Novo’s remedies and don’t replicate newer information on high-dose Wegovy.
Lilly has denied these allegations, saying its promoting is predicated on accessible scientific proof.
That case is about how the businesses market their competing medicines, whereas the shareholder lawsuit towards Novo focuses on what the corporate instructed its personal traders about CagriSema’s scientific trial design and outcomes.
For now, the shareholder case strikes into discovery, the place traders will try and show that Novo violated securities legal guidelines. Novo could have the chance to proceed defending itself earlier than any trial on the deserves.
